Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Kymera Therapeutics ( (KYMR) ) is now available.
On June 25, 2025, Kymera Therapeutics held its Annual Meeting of Shareholders, where three key proposals were voted on. Shareholders elected Jeffrey Albers and Felix J. Baker as Class II directors for a three-year term, approved the compensation of named executive officers on a non-binding basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
Kymera Therapeutics benefits from strong technical momentum and strategic corporate partnerships, which enhance its growth outlook despite current financial challenges. The company’s substantial cash reserves and promising pipeline developments further support future potential, although the negative cash flow and earnings remain significant risks.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
Kymera Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of targeted protein degradation therapies. The company aims to address unmet medical needs through its innovative therapeutic approaches.
Average Trading Volume: 904,481
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.03B
Learn more about KYMR stock on TipRanks’ Stock Analysis page.